A carregar...
Phase 1 Parkinson’s Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated
INTRODUCTION: There is a need for new therapies in Parkinson’s disease that may help to address known limitations of current options. PF-06649751 is a novel, highly selective dopamine D1/D5 agonist targeted for Parkinson’s disease treatment. METHODS: The safety, pharmacokinetics, and pharmacodynamic...
Na minha lista:
| Publicado no: | Neurol Ther |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Healthcare
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6283789/ https://ncbi.nlm.nih.gov/pubmed/30361858 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40120-018-0114-z |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|